drugset / Trial / NCT00071136

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00071136

Phase 1/2 Completed 48 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.

Timeline

Start
2003-12
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule
Subject Pemetrexed Small molecule

Indications